<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6753">
  <stage>Registered</stage>
  <submitdate>2/08/2017</submitdate>
  <approvaldate>2/08/2017</approvaldate>
  <nctid>NCT03306394</nctid>
  <trial_identification>
    <studytitle>An Early Access Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer</studytitle>
    <scientifictitle>An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002311-18</secondaryid>
    <secondaryid>CL3-95005-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Trifluridine/Tipiracil hydrochloride (S95005)

Experimental: S95005 - Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/mÂ²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.


Treatment: drugs: Trifluridine/Tipiracil hydrochloride (S95005)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Adverse Events [safety and tolerability]</outcome>
      <timepoint>Through 28 days following last administration of study medication</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Abnormalities in laboratory assessment</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Abnormalities in performance status (ECOG)</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Abnormalities in vital signs</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) - time from the date of first study drug intake until the date of the investigator-assessed disease progression or death due to any cause whichever occurs first.</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life using the questionnaire EQ-5D</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life using the questionnaire EORTC QLQ-C30</outcome>
      <timepoint>Through study completion, an average of 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or Female participant aged =18 years old.

          -  Has definitive histologically confirmed adenocarcinoma of the colon or rectum.

          -  Has metastatic lesion(s).

          -  Has received at least 2 prior regimens of standard chemotherapies (including
             fluoropyrimidines, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and at
             least one of the anti-EGFR monoclonal antibodies for RAS wild-type patients) for mCRC
             and is refractory or intolerant to those chemotherapies or is not candidate for those
             chemotherapies.

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 during the
             screening period.

          -  Is able to take medications orally (i.e., no feeding tube).

          -  Has adequate organ function.

          -  Women of childbearing potential must have been tested negative in a serum pregnancy
             test within 7 days prior to first day of test drug administration. Female participants
             of childbearing potential and male participants with partners of childbearing
             potential must agree to use a highly effective method of birth control during the
             study and for 6 months after the discontinuation of study medication. Women and female
             partners using hormonal contraceptive must also use a barrier method.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnancy, breastfeeding or possibility of becoming pregnant during the study.

          -  Eligible for enrolment into another available ongoing clinical study of trifluridine /
             tipiracil.

          -  Has previously received trifluridine / tipiracil or hypersensitivity to the active
             substances or to any of the excipients of trifluridine / tipiracil.

          -  Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or
             glucose-galactose malabsorption.

          -  Has certain serious illness or medical condition(s) described in the protocol.

          -  Has had certain other recent treatment e.g. major surgery, anticancer therapy,
             radiation therapy, participation in another interventional study, within the specified
             time frames prior to first day of study drug administration.

          -  Has unresolved toxicity of greater than or equal to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia,
             alopecia, skin pigmentation, and platinum-induced neurotoxicity).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>18/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Chris O'Brien Lifehouse Oncology - Camperdown</hospital>
    <hospital>St Vincent's Hospital The Kinghorn Cancer Centre - Darlinghurst</hospital>
    <hospital>St Vincent's Hospital (Melbourne) Cancer Centre - Fitzroy</hospital>
    <hospital>The Canberra Hospital Cancer,Ambulatory &amp; Community Health Service (CACHS) Bldg 19 - Garran</hospital>
    <hospital>Royal Brisbane &amp; Women's Hospital Clinical Research Unit - Herston</hospital>
    <hospital>Cabrini Hospital Cabrini Haematology and Oncology Centre - Malvern</hospital>
    <hospital>Perth Oncology - Mount Hospital - Perth</hospital>
    <hospital>The Queen Elizabeth Hospital Haematology and Oncology Unit - Woodville</hospital>
    <postcode>NSW 2050 - Camperdown</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>SA 5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Rijeka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Arras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Avignon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Chambray Les Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Levallois Perret</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montbeliard</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>TOULOUSE cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Benevento</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola (ForlÃ¬)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pescara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rimini</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano (mi)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Giovanni Rotondo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Almada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Maribor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Edirne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kayseri</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Institut de Recherches Internationales Servier</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to collect additional safety and efficacy data during treatment
      with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer
      (mCRC).

      Eligible patients may receive an early access to trifluridine / tipiracil through this
      clinical study until progression of disease, unacceptable toxicity, investigator decision,
      patient refusal or until market authorization or reimbursement has been granted by the
      relevant Authority of the country where that patient is treated or until trifluridine /
      tipiracil is available by a doctor's prescription or can be accessed from another source or
      Sponsor decision.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03306394</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Institut de Recherches Internationales Servier Clinical Studies Department</name>
      <address />
      <phone>+33 1 55 72 43 66</phone>
      <fax />
      <email>clinicaltrials@servier.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>